1. Combination Cediranib Plus Olaparib Improves PFS in Platinum-Resistant Ovarian Cancer
Cediranib in combination with olaparib (Lynparza) demonstrated an improvement in progression-free survival (PFS) when used as treatment for patients with platinum-resistant ovarian cancer (PROC). However, the difference in PFS compared with chemotherapy did not achieve statistical significance, according to a randomized trial. more details...


2. FDA Fast Track Designation Granted to Navicixizumab for Heavily Pretreated Ovarian Cancer
The FDA has granted a fast track designation to navicixizumab (OMP-305B83) for the treatment of patients with high-grade ovarian, primary peritoneal, or fallopian tube cancer who have received ≥3 prior therapies and/or prior bevacizumab (Avastin) more details...


3. Expert Offers Advice for Women With Ovarian Cancer
As the fifth leading cause of death among women in the US, ovarian cancer awareness is recognized in the month of September to educate the public on symptoms, risks and treatment options. more details...